BARRIER METHODS IN THERAPY OF ALLERGIC RHINITIS IN CHILDREN


N.A. Geppe, I.M. Farber, U.S. Malyavina, V.S. Malyshev, S.I. Shatalina, M.D. Velikoretskaya, N.A. Krylova

Department of Children's Diseases SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH, Moscow
Currently, allergy problem is extremely urgent worldwide, and allergic rhinitis (AR) is one of the most common allergic diseases in children. An open observational study of the safety, tolerability and efficacy of the drug Prevalin in the form of a intranasal spray in children with mild to moderate seasonal and perennial AR (group 1) and in children with mild to moderate AR combined with mild to moderate bronchial asthma (group 2) was performed. In some children with AR, Prevalin was administred in combination with antihistamines and irrigation therapy (group 3). Each group consisted of 20 children aged 6 to 14 years, the average age 9.4 ± 2.5 years. Within 3 weeks, nasal breathing blockade, discharge from the nose, sneezing, itching of the nose, itchy eyes, watery eyes were appraised by points. All the children underwent the pulmonary function test using computer bronchophonography (CBPG). Distinct effect of Prevalin on clinical symptoms in patients with AR and AR in combination of bronchial asthma was revealed. The symptoms have quickly disappeared when Prevalin was administered in combination with antihistamines. Reducing the symptoms of AR was accompanied with improvement of respiratory function according CBPG. Prevalin is recommended as the drug of choice for barrier symptomatic treatment of mild to moderate AR in children, including when AR is combined with bronchial asthma.

Literature


  1. Mercer M.J., Joubert G., Ehrlich R.I. Socioeconomic status and prevalence of allergic rhinitis and atopic eczema symptoms in young adolescents. Pediatr. Allergy. Immunol. 2004;15(3):234–41.
  2. Weiland S.K. Hiising A., Strachan D.P. ISAAC Phase One Study Group. Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children. Occup. Environ. Med. 2004;61(7):609–15.
  3. РАДАР. Аллергический ринит у детей. Рекомендации и алгоритм при детском аллергическом рините. Научно-практическая программа / Под ред. В.А. Ревякина, Н.А. Дайхес, Н.А. Геппе. М., 2015.
  4. Asher M.I., Montefort S., Bjorksten B., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43.
  5. Bjorksten B., Clayton T., Ellwood P., et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatric Allergy & Immunology. 2008;19(2):110–24.
  6. Bousquet J. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl. 86):8–160.
  7. Ревякина В.А. Современный взгляд на проблему аллергических ринитов у детей. Лечащий врач. 2007;3:22–7.
  8. Горячкина Л.А., Передкова Е.В., Астафьева Н.Г. Клиническая аллергология и иммунология. Руководство для практикующих врачей. Глава Поллинозы / Под ред. Л.А. Горячкиной, К.П. Кашкина. М., 2009;351–62.
  9. Hammad H., Lambrecht B.N. Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity. 2015;43(1):29–40.
  10. Bart N. Lambrecht and Hamida Hammad. Asthma: The importance of dysregulated barrier. Immunity. Eur. J. Immunol. 2013. 43: 3125–37.
  11. Геппе Н.А., Снегоцкая М.Н., Конопелько О.Ю. Новое в профилактике и терапии сезонных аллергических ринитов. Лечащий врач. 2012;1:39–42.
  12. Цывкина А.А., Лусс Л.В., Царев С.В., Шартанова Н.В. Эффективность и безопасность спрея «Превалин» в терапии аллергического ринита. Рос. аллергол. журн. 2012;5:55–9.
  13. Геппе Н.А., Шаталина С.И. Бронхолитическая эффективность различных препаратов у детей с бронхиальной астмой. Сборник тезисов XIX Российского национального конгресса «Человек и лекарство». М., 23–27 апреля 2012. 253. с.
  14. Shatalina S.I., Geppe N.A., Kolosova N.G., Malishev V.S. CBPG – method of assessment of respiratory function in asthmatic children. ERS Annual Congress 2013, Barselona, 07–11.09.2013.
  15. Кондюрина Е.Г., Зеленская В.В. Роль терапии аллергического ринита в профилактике атопического марша. Вопр. соврем. педиатрии: 2005;4(1):26–30.
  16. Stoelzel К., Bothe G., Chong P. W., Lenarz M. Safety and efficacy of Nasya/Prevalin in reducing symptoms of allergic rhinitis. Clin. Respir. J. 2014;8:382–90.
  17. Global Initiative for Asthma. Global strategy for asthma management and prevention (GINA). Updated 2014.
  18. Геппе Н.А., Старостина Л.С., Батырева О.В., Фарбер И.М., Озерская И.В., Малявина У.С. Взгляд педиатра на ринит у детей. Подход к терапии деконгестантами. РМЖ, Педиатрия. 2013;2:66–71.
  19. Инструкция по применению лекарствен-ного препарата Превалин кидс РУ №ФСЗ 2012/11782 от 24.04.2012.


About the Autors


N.A. Geppe – Doctor of Medical Sciences. Prof, Director of the University Children's Clinical Hospital, Head of the Department of Children’s Diseases SBEI HPE First MSMU n.a. I.M. Sechenov of RMPH, Moscow; e-mail: geppe@mail.ru


Similar Articles


Бионика Медиа